Medical Condition News

RSS

Ampio completes enrollment phase of Australian Ampion In Knee trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that it is has completed the expanded patient enrollment phase of its Ampion In Knee (AIK) trials in Australia.

3 Jan 2012

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma.

3 Jan 2012

Combination of biomarkers indicates high risk of Alzheimer's in the future

Physician Oskar Hansson and his research group are studying biomarkers - substances present in spinal fluid and linked to Alzheimer's disease. The group has studied close to 140 people with mild memory impairment, showing that a certain combination of markers (low levels of the substance beta-amyloid and high levels of the substance tau) indicate a high risk of developing Alzheimer's disease in the future.

3 Jan 2012

InSightec completes enrollment in ExAblate Neuro clinical study for Essential Tremor

InSightec Ltd, the global leader in MR guided Focused Ultrasound therapy, announced today that it has completed enrollment in the world's first feasibility study evaluating the use of MRgFUS for treatment of Essential Tremor, using ExAblate Neuro at University of Virginia, Charlottesville, Virginia.

3 Jan 2012

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

Ossianix, Inc. today announced a strategic investment by H. Lundbeck A/S in the form of a Convertible Promissory Note. The proceeds from Lundbeck's investment is expected to allow Ossianix to generate biopharmaceuticals for the treatment of nervous system disorders by utilizing Ossianix's proprietary single domain antibody platform modeled on the shark vNAR structure.

3 Jan 2012

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

Cell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will review CTI's resubmitted New Drug Application (NDA) for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who failed two or more lines of prior therapy.

3 Jan 2012

Adiponectin may play a role in development of all-cause dementia and AD in women

A hormone derived from visceral fat called adiponectin may play a role as a risk factor for development of all-cause dementia and Alzheimer disease (AD) in women, according to a study published Online First by the Archives of Neurology, one of the JAMA/Archives journals.

3 Jan 2012

DBS safe and effective for treatment-resistant depression in patients with unipolar MDD or BP

A new study shows that deep brain stimulation (DBS) is a safe and effective intervention for treatment-resistant depression in patients with either unipolar major depressive disorder (MDD) or bipolar ll disorder.

3 Jan 2012

Adolescents diagnosed with schizophrenia appear to show greater brain GM volume loss

Adolescents diagnosed with schizophrenia and other psychoses appear to show greater decreases in gray matter volume and increases in cerebrospinal fluid in the frontal lobe compared to healthy adolescents without a diagnosis of psychosis, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Jan 2012

Children exposed to maternal GDM and low SES more likely to develop ADHD

Children exposed to maternal gestational diabetes mellitus and low socioeconomic status, particularly in combination, appear to be at an increased risk of developing childhood ADHD, according to a report published Online First by Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

3 Jan 2012

Sex, race and dementia may influence risk of mortality in patients with PD

Demographics and clinical factors appear to be associated with survival in patients with Parkinson disease (PD), and the presence of dementia is associated with a significant increase in mortality, according to a report in the January issue of Archives of Neurology, one of the JAMA/Archives journals.

2 Jan 2012

Low SES, maternal gestational diabetes may increase risk of ADHD in six year olds

In the first study of its kind, researchers at Queens College and Mount Sinai School of Medicine have found that low socioeconomic status (SES) and maternal gestational diabetes together may cause a 14-fold increased risk of attention deficit hyperactivity disorder (ADHD) in six year olds.

2 Jan 2012

CSF Aβ42 levels appear to be decreased before patients with MCI develop AD dementia

Cerebrospinal fluid levels of Aβ42 appear to be decreased at least five to 10 years before some patients with mild cognitive impairment develop Alzheimer disease (AD) dementia whereas other spinal fluid levels seem to be later markers of disease, according to a report in the January issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Jan 2012

FDA notes shortage of ADHD medicines

According to the U.S. Food and Drug Administration (FDA) drugs to treat attention deficit hyperactivity disorder (ADHD) are in such short supply that hundreds of patients complain daily to the agency that they are unable to find a pharmacy with enough pills to fill their prescriptions.

2 Jan 2012

Major European medical center includes Critical Diagnostics' Presage ST2 Assay for cardiac care

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, announced today that a major European medical center, Hospital Germans Trias i Pujol in Barcelona Spain, is now using the company's Presage ST2 Assay for routine care and management of their heart failure patients.

2 Jan 2012

AddisonsDisease.Net celebrates ten years of service

Teleplexus, Inc. is pleased to announce the ten-year anniversary of AddisonsDisease.Net, its premier Addison's disease support resource. Born by design on New Year's Day in 2002, AddisonsDisease.Net began service on this day which is seen around the world as a time of renewal and optimism.

2 Jan 2012

Sleep apnea may impact health of young diabetics

A new study suggests that young diabetics may be struggling to get a good night's sleep, resulting in worse control of their blood sugar, poorer school performance and misbehavior.

2 Jan 2012

Study finds risk factors associated with exfoliation syndrome

When it comes to whether or not you will develop exfoliation syndrome (ES) -- an eye condition that is a leading cause of secondary open-angle glaucoma and increased risk of cataract as well as cataract surgery complications -- age, gender and where you live does matter.

2 Jan 2012

Issue of NCDs in post-conflict countries must be addressed, say experts

Countries recovering from war are at risk of being left to their own devices in tackling non communicable diseases, leaving an "open door" for exploitation by alcohol, tobacco and food companies, health experts warn.

2 Jan 2012

ProStrakan announces FDA approval for Transmucosal Immediate Release Fentanyl REMS Access program

ProStrakan, Inc., a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that the U.S. Food and Drug Administration has approved the TIRF (Transmucosal Immediate Release Fentanyl) REMS Access program.

31 Dec 2011

Medical Condition News

Ampio completes enrollment phase of Australian Ampion In Knee trials

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

Combination of biomarkers indicates high risk of Alzheimer's in the future

InSightec completes enrollment in ExAblate Neuro clinical study for Essential Tremor

Lundbeck invests in Ossianix to focus on biotherapeutics for CNS disorders

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDA

Adiponectin may play a role in development of all-cause dementia and AD in women

DBS safe and effective for treatment-resistant depression in patients with unipolar MDD or BP

Adolescents diagnosed with schizophrenia appear to show greater brain GM volume loss

Children exposed to maternal GDM and low SES more likely to develop ADHD

Sex, race and dementia may influence risk of mortality in patients with PD

Low SES, maternal gestational diabetes may increase risk of ADHD in six year olds

CSF Aβ42 levels appear to be decreased before patients with MCI develop AD dementia

FDA notes shortage of ADHD medicines

Major European medical center includes Critical Diagnostics' Presage ST2 Assay for cardiac care

AddisonsDisease.Net celebrates ten years of service

Sleep apnea may impact health of young diabetics

Study finds risk factors associated with exfoliation syndrome

Issue of NCDs in post-conflict countries must be addressed, say experts

ProStrakan announces FDA approval for Transmucosal Immediate Release Fentanyl REMS Access program

This International Women’s Day, Meet the Scientist Changing Women’s Healthcare

Microphysiological systems in drug discovery

Considerations for taking ASO discovery programs into animal models

Latest News